MarketLens

Is Regeneron's Eylea HD Enough to Fend Off Biosimilars and Rivals

4 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Target's $2 Billion Bet Enough to Revitalize Growth

6 months ago

Is Q2 Holdings' Innovation Enough to Counter Market Skepticism

3 months ago

Brookdale's Occupancy Gains: Not Enough to Outrun Debt and Disappointment

2 months ago

Is SmartRent's Sales Scaling Strategy Enough to Drive Growth

4 months ago

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth

Regeneron Pharmaceuticals outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance,...

REGN

News•2 weeks ago

EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward

EyePoint's wet-AMD drug LUGANO missed its primary endpoint, lowering estimated approval probability to 30% and raising regulatory risk. Strong durability results still support DURAVYU's commercial pot...

Stock News•3 weeks ago

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

Eyconis dosed first patients in OVERTURE, a Phase 1b/2a trial of EYC-0305, a long-acting anti-VEGF therapy for treatment-naïve wet age-related macular degeneration, targeting six-month or longer dosin...

ASND

Breaking News

Clinical Trials (Phase I, II, III)

Creator Economy

Crude Oil (WTI/Brent)

Top Headlines

View More →

Stock News•2 hours ago

Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.

Stock News•2 hours ago

Viral AI Dommer Tweet: Engineered Panic?

Stock News•3 hours ago

Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.

Stock News•4 hours ago

Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.

Stock News•6 hours ago

Is Regeneron's Eylea HD Enough to Fend Off Biosimilars and Rivals

Exclusive Content for Pro Members

Related Articles

Is Target's $2 Billion Bet Enough to Revitalize Growth

Is Q2 Holdings' Innovation Enough to Counter Market Skepticism

Brookdale's Occupancy Gains: Not Enough to Outrun Debt and Disappointment

Is SmartRent's Sales Scaling Strategy Enough to Drive Growth

Category

You may also like

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth

EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.

Viral AI Dommer Tweet: Engineered Panic?

Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.

Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.

Warren Buffett Made Apple Berkshire Hathaway's Single Largest Stock Position: $10,000 Invested 10 Years Ago Would Be Worth Roughly $122,400 Today